The global acetaminophen market, valued at USD 9.8 billion in 2022, is expected to experience steady growth over the next decade. By 2033, the market is projected to reach USD 15.2 billion, with a compound annual growth rate (CAGR) of 4.2% during the forecast period. This expansion is driven by the increasing demand for pain relief medications, growing awareness of over-the-counter (OTC) treatments, and the widespread use of acetaminophen for fever and pain management.
Acetaminophen, a widely used analgesic and antipyretic, continues to dominate the global market due to its efficacy, safety profile, and affordability. According to recent findings by Future Market Insights, the oral route of administration remains the leading method, accounting for approximately 92.4% of the market share in 2022. Its ease of use, availability in various formulations (tablets, capsules, liquid), and suitability for self-medication contribute significantly to its popularity among consumers.
As the market grows, factors such as increasing healthcare access, rising incidences of chronic pain conditions, and the ongoing demand for OTC medicines in both developed and emerging markets are expected to fuel acetaminophen consumption. Additionally, the market is benefiting from the increasing preference for generic acetaminophen products, which offer affordable alternatives to branded medications.
Key Takeaways:
- The global acetaminophen market is projected to grow from USD 9.8 billion in 2022 to USD 15.2 billion by 2033, at a CAGR of 4.2%.
- The oral route of administration continues to dominate the market, holding a share of 92.4% in 2022.
- Rising demand for OTC pain relief solutions and increasing healthcare accessibility are key drivers of market growth.
- The shift towards affordable generic acetaminophen products is supporting widespread market adoption.
Competitive Landscape
Leading companies in the worldwide acetaminophen market are making investments in collaborations, partnerships, and distribution contracts to expand their reach internationally.
Because there are so many cases of untreated pain, analgesic manufacturers are concentrating on the Asia-Pacific and African regions. Due to the rising opioid misuse, the major players are also concentrating on creating drug formulations without opioids.
- Sanofi successfully acquired Principia Biopharma Inc. in 2020 to expand its expertise in autoimmune and allergy diseases.
- Sandoz, a division of Novartis, sold its USA business unit to Aurobindo Pharma in September 2018. Aurobindo Pharma was able to expand its product offering in the acetaminophen market due to this acquisition.
Similarly, recent developments related to companies manufacturing acetaminophen drugs have been tracked by the team at Future Market Insights, which are available in the full report.
Key Companies Profiled
Pfizer Inc.; Sanofi; Janssen Pharmaceuticals.; Bayer AG; GlaxoSmithKline plc; Bristol-Myers Squibb and Company; Teva Pharmaceutical Industries Ltd; Cardinal Health Inc.; Perrigo Company.; Novartis AG; Sun Pharmaceutical Industries Ltd; Abbott; Mallinckrodt Pharmaceuticals; Procter & Gamble Company
Request a Sample Report Now to get Premium Insights: https://www.fmisamplereport.com/sample/rep-gb-14325
Key Market Segments Covered in Acetaminophen Drugs Industry Research
By Product:
- Acetaminophen
- Acetaminophen with Opioids
- Others
By Route of Administration:
- Oral
- Injectable
- Others
By Sales:
- OTC (Over-the-counter)
- Rx (Prescription)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- E-commerce
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
